Rituximab Reduces Immunogenicity and Increases Complete Remissions without Minimal Residual Disease in Relapsed/Refractory Hairy Cell Leukemia Patients Receiving Moxetumomab Pasudotox
R. J. Kreitman(National Institutes of Health), Ira Pastan(National Cancer Institute), Mark Raffeld(National Cancer Institute), Liqiang Xi(Center for Cancer Research), Katherine R. Calvo(National Institutes of Health Clinical Center), Julie Feurtado(National Institutes of Health), Lacey James(National Institutes of Health), Evgeny Arons(National Institutes of Health), Hao‐Wei Wang(Fu Jen Catholic University), Hong Zhou(National Institutes of Health), Irina Marić(Center for Cancer Research), Raul C. Braylan(Center for Cancer Research), Constance M. Yuan(National Cancer Institute)
Cited by 1
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
|New England Journal of Medicine|2014|889
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
|Journal of Clinical Investigation|2018|519
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
|Journal of Clinical Oncology|2020|422